Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:39:09.715Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:39:09.715Z.
Quote observation: 2026-10-06T18:30:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 62e543f524ee8633d6080f2a553f9cbd6b945788c6a084cb4464cef9d8d253d7
FORWARD PE RATIO
N/A
Exicure, Inc.
Market Cap
$7.08M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Exicure, Inc. (XCUR) | $7.08M | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.07M | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.07M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.05M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.20M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.21M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.78M | N/A |
| Aclarion, Inc. (ACON)vs › | $6.64M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
